Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "Mumbai"

271 News Found

India is emerging as a favourable destination to conduct clinical trials: PwC-USAIC Report
News | May 05, 2023

India is emerging as a favourable destination to conduct clinical trials: PwC-USAIC Report

Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India


Atul appoints Rangaswamy Iyer as Independent Director
People | April 29, 2023

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years


TPAG organizes Thalassemia & SCD prevention discussion
News | April 29, 2023

TPAG organizes Thalassemia & SCD prevention discussion

The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally


Apollo launches Genomics Institute in Chennai
Biotech | April 25, 2023

Apollo launches Genomics Institute in Chennai

Apollo continues to invest in genomics technology and research for better patient care


Emcure Pharmaceuticals bags Merit Award at HIV Congress 2023
News | April 08, 2023

Emcure Pharmaceuticals bags Merit Award at HIV Congress 2023

The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.


Getinge to boost scalability and deepen healthcare access in India
Medical Device | April 01, 2023

Getinge to boost scalability and deepen healthcare access in India

Getinge has a strong market share in India within several product segments


CAHO and Dozee join hands to discuss emerging role of AI in healthcare
Digitisation | March 30, 2023

CAHO and Dozee join hands to discuss emerging role of AI in healthcare

70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai


Lupin announces completion of pharmacovigilance inspection by USFDA
Drug Approval | March 27, 2023

Lupin announces completion of pharmacovigilance inspection by USFDA

The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide


Lupin receives approval from USFDA for Brexpiprazole Tablets
Drug Approval | March 22, 2023

Lupin receives approval from USFDA for Brexpiprazole Tablets

Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)